Desvenlafaxine for Anxiety Treatment

Introduction to Desvenlafaxine

Desvenlafaxine allows once-daily dosing due to its sufficiently long elimination half-life, reaching steady-state plasma concentrations within 4-5 days, in patients with anxiety and depression 1
No dose titration is typically required for desvenlafaxine, unlike venlafaxine immediate-release which may require twice- or thrice-daily dosing, in patients with anxiety and depression 1

Common adverse effects of desvenlafaxine include sustained hypertension, increased blood pressure, and increased pulse, which require regular monitoring of blood pressure and pulse 1
Desvenlafaxine can cause suicidal thinking and behavior, particularly in patients under age 24, and requires monitoring for suicidal ideation 1
Behavioral activation, agitation, hypomania, or mania are potential risks of desvenlafaxine treatment, and require careful monitoring 1
Serotonin syndrome is a potential risk of desvenlafaxine treatment, especially with concomitant MAOIs, which are contraindicated 1
Discontinuation syndrome can occur if desvenlafaxine is stopped abruptly, and requires a slow taper 1

For patients with comorbid hypertension or cardiovascular concerns, alternative agents like vilazodone may be considered instead of desvenlafaxine, due to its potential to increase blood pressure 1
Height, weight, pulse, and blood pressure should be monitored at baseline and during desvenlafaxine treatment 1
No specific laboratory tests are routinely recommended for desvenlafaxine treatment, but suicidal ideation should be assessed, particularly in the first weeks after initiation 2
Response to desvenlafaxine treatment should be evaluated after 8 weeks, and alternative medications considered if response is inadequate 3

Desvenlafaxine, as an SNRI, inhibits the reuptake of both serotonin and norepinephrine, and has shown efficacy in reducing anxiety symptoms associated with depression, according to the American Academy of Child and Adolescent Psychiatry 4, 5
Levomilnacipran, also an SNRI, inhibits the reuptake of both serotonin and norepinephrine, and is currently marketed in the United States as one of the SNRI options, as reported by the American Academy of Child and Adolescent Psychiatry 5

SNRIs like desvenlafaxine and levomilnacipran can cause adverse effects including diaphoresis, dry mouth, abdominal discomfort, nausea, vomiting, diarrhea, dizziness, headache, tremor, insomnia, somnolence, decreased appetite, and weight loss, and have been associated with sustained clinical hypertension, increased blood pressure, and increased pulse, as noted by the American Academy of Child and Adolescent Psychiatry 5, 6

Individual patient factors such as comorbidities, medication interactions, and previous treatment responses should be considered, as suggested by the American Academy of Child and Adolescent Psychiatry and Neuropsychopharmacology 5, 7
For patients with comorbid hypertension, vilazodone may be preferred over SNRIs like desvenlafaxine and levomilnacipran, which can increase blood pressure, according to the American Academy of Child and Adolescent Psychiatry 5, 6

The American College of Physicians suggests that venlafaxine demonstrated superior response and remission rates compared to fluoxetine in one fair-quality trial for depression with anxiety symptoms, indicating a potential advantage for the SNRI class, though evidence is limited 8
The American College of Physicians also notes that 10 fair-quality head-to-head trials showed no difference in efficacy between various second-generation antidepressants, including venlafaxine compared to sertraline, for treating anxiety associated with major depressive disorder 9